NeuroOne Medical Technologies
NMTC
30 hedge funds and large institutions have $9.18M invested in NeuroOne Medical Technologies in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 2 closing their positions.
600% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 2
460% more capital invested
Capital invested by funds: $1.64M → $9.18M (+$7.54M)
67% more funds holding
Funds holding: 18 → 30 (+12)
20.91% more ownership
Funds ownership: 6.25% → 27.16% (+21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
Bleichroeder LP
New York
|
+$2.46M |
| 2 |
SCM
Sio Capital Management
New York
|
+$2.17M |
| 3 |
BA
Bard Associates
Chicago,
Illinois
|
+$1.14M |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$923K |
| 5 |
Renaissance Technologies
New York
|
+$289K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$83.8K |
| 2 |
JP Morgan Chase
New York
|
-$52 |
NMTC Hedge Fund Activity: Q2 2025 in Review
30 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in NeuroOne Medical Technologies (NMTC) for Q2 2025, worth a combined $9.18M — up 460% from $1.64M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new NMTC positions and 2 closed out — a net gain of 12 holders — while 5 added to existing stakes and 0 trimmed.
The largest buyer was Bleichroeder LP, opening a new position worth an estimated $2.46M. The largest seller was Goldman Sachs, exiting entirely with an estimated $83.8K sold.
- 30 institutional investors held NeuroOne Medical Technologies (NMTC) as of Q2 2025, up from 18 in Q1 2025.
- Funds reported $9.18M of NeuroOne Medical Technologies stock for Q2 2025, up 460% quarter-over-quarter.
- 14 funds opened new NeuroOne Medical Technologies positions in Q2 2025 and 2 closed out, a net change of +12 holders.
- The largest NeuroOne Medical Technologies buyer in Q2 2025 was Bleichroeder LP, an estimated $2.46M added.
- The largest NeuroOne Medical Technologies seller in Q2 2025 was Goldman Sachs, an estimated $83.8K sold.
Based on aggregated 13F filings for Q2 2025.